Findings show that IL-1β influences lung cancer growth and affects treatment resistance, indicating its complex role in therapy outcomes.
Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.
No takes yet. Share an insight, caveat, or question.
Rébé et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: